Get access to our best features
Get access to our best features
Published 3 months ago

FDA Mandates Changes to iPLEDGE Program for Isotretinoin

Summary by
Isotretinoin manufacturers have 6 months to make five changes to existing iPLEDGE Risk Evaluation and Mitigation Strategy (REMS) requirements for isotretinoin.
Ground News Article Assistant
Not enough coverage to generate an Article Assistant.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.

To view factuality data please Upgrade to Premium


To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)

Similar News Topics